{"entity":{"id":"pb-212-vmt-alpha-net","kind":"drug","name":"Lead-212 VMT-alpha-NET","aka":["212Pb-VMT-alpha-NET","[212Pb]VMT-α-NET","203Pb-VMT-alpha-NET (imaging analogue)"],"tldr":"A drug that targets a marker on neuroendocrine tumour cells is being tested with two versions of a radioactive metal: one lets doctors see where the tumour is on a scan, and the other delivers a strong, short-range dose of radiation to kill the tumour cells.","summary":"VMT-alpha-NET is Perspective Therapeutics' targeted alpha-particle therapy (TAT) programme for somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumours (NETs), pheochromocytoma/paraganglioma and meningioma. The same peptide is labelled with lead-203 for SPECT/CT imaging (used to plan a patient-specific kidney radiation-dose limit) and with the alpha-emitting isotope lead-212 for therapy.\n\nThe ongoing multicentre, open-label phase 1/2a trial (ClinicalTrials.gov NCT05636618) is a dose-escalation and dose-expansion study in up to about 300 adult, PRRT-naive patients with unresectable or metastatic SSTR2-positive NETs, bronchial NETs, pheochromocytoma/paraganglioma, or meningioma; dosing is by intravenous infusion roughly every 8 weeks. The FDA granted Fast Track designation in September 2022 for SSTR2-positive NETs regardless of prior treatment. A separate single-centre phase 1 study in PRRT-refractory patients (NCT06148636) is under way at the University of Iowa.\n\nInterim data presented at ASCO-GI and AACR in 2026 (data cut-offs through April 2026) reported, across dose cohorts up to 64 patients, no dose-limiting toxicities, treatment-related discontinuations or grade 5 events, with grade 3+ adverse events in roughly a third of patients (mostly non-renal, non-myelosuppressive); in evaluable patients from the lower dose cohorts, 76% remained progression-free and alive, and an objective response rate of about 39-44% (RECIST v1.1) was reported in Cohort 2 (5 mCi per dose). VMT-alpha-NET has not received marketing authorisation in any jurisdiction; the programme is still determining its recommended phase 2 dose.","status":"phase-2","asOf":"2026-09-22","links":[{"label":"Perspective Therapeutics: VMT-alpha-NET pipeline page","url":"https://perspectivetherapeutics.com/pipeline/vmt-alpha-net"},{"label":"ClinicalTrials.gov: NCT05636618","url":"https://clinicaltrials.gov/study/NCT05636618"},{"label":"Perspective Therapeutics: updated interim data at AACR 2026","url":"https://www.globenewswire.com/news-release/2026/04/20/3276793/0/en/perspective-therapeutics-presents-updated-interim-data-of-212pb-vmt-%CE%B1-net-in-its-ongoing-phase-1-2a-clinical-trial-at-the-2026-aacr-annual-meeting.html"},{"label":"Perspective Therapeutics: first patient dosed press release, 2023","url":"https://perspectivetherapeutics.com/pr/perspective-therapeutics-announces-first-patient-dosed-in-a-phase-1-study-of-212pbvmtnet-to-treat-refractory-or-relapsedneuroendocrine-tumors"}],"tags":["alpha therapy","SSTR2","neuroendocrine tumours","lead-212","phase 1/2"],"related":["alphamedix","itm-11","lutathera","pb-212"],"indications":["neuroendocrine"],"sections":[],"technologies":["targeted-alpha-therapy"],"targets":["sstr2"],"drugs":[],"companies":["perspective-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05636618"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"VMT-alpha-NET","modality":"alpha therapy","mechanism":"A somatostatin receptor subtype 2 (SSTR2)-targeting peptide that can be radiolabelled either with lead-203 (a gamma emitter, for SPECT imaging and dosimetry planning) or with lead-212 (an in-vivo alpha-emitter generator via its decay chain), delivering high-linear-energy-transfer alpha radiation directly to SSTR2-expressing neuroendocrine tumour cells.","approvals":[],"mechanismSteps":[],"dosing":{"route":"Intravenous infusion","schedule":"Dose-escalation cohorts from 2.5 to 6.0 mCi per dose, approximately every 8 weeks, up to 4 administrations","source":"https://www.globenewswire.com/news-release/2026/04/20/3276793/0/en/perspective-therapeutics-presents-updated-interim-data-of-212pb-vmt-%CE%B1-net-in-its-ongoing-phase-1-2a-clinical-trial-at-the-2026-aacr-annual-meeting.html"},"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pb-212-vmt-alpha-net/","neighbours":{"drug":[{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/"},{"id":"alphamedix","kind":"drug","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/"},{"id":"pb-212-psv359","kind":"drug","name":"Lead-212 PSV359","route":"/drugs/pb-212-psv359/"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"}],"isotope":[{"id":"pb-212","kind":"isotope","name":"Lead-212","route":"/isotopes/pb-212/"}],"indication":[{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"}],"technology":[{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"company":[{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/"}],"trial":[{"id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/"}]}}